Payment overview · 2025
General Payments
$2,043.22
84 reported records · 27 companies
Healthcare provider profile · identity verified
Pranjalkumar H Patel, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TRACY, CA · NPI 1225233133
Verified facts
What the public records show
CMS Open Payments records show Pranjalkumar H Patel, M.D. received $2,043.22 in general payments during 2025 across 84 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 45 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Prolia, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 253 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 410 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 516 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $417.91 | 20.4% | 14 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $377.39 | 18.5% | 10 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $305.71 | 15.0% | 14 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $112.17 | 5.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $101.20 | 5.0% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $83.91 | 4.1% | 4 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $59.46 | 2.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $58.77 | 2.9% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $56.83 | 2.8% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.68 | 2.8% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.04 | 2.4% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $43.70 | 2.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $38.33 | 1.9% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $34.65 | 1.7% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $26.30 | 1.3% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $26.02 | 1.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $22.42 | 1.1% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.51 | 1.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $20.81 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.44 | 0.9% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.80 | 0.9% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $17.80 | 0.9% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.73 | 0.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.64 | 0.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.28 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $13.95 | 0.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.77 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,043.22 | 84 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $417.91 | 14 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $305.71 | 14 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $212.95 | 7 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $184.90 | 13 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $143.15 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $115.15 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $72.23 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $59.46 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $59.46 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $56.83 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $43.70 | 2 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $43.14 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.45 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.01 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $40.97 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $40.97 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $40.97 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $38.33 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $34.65 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.40 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $26.30 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $26.02 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $24.19 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.79 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.51 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.73 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.64 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.23 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $13.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 207 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 43 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 410 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 82 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 46 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
82 | 53 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
69 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
253 | 80 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 67 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
205 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
207 | 67 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
43 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
410 | 104 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
46 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
516 | 92 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1886 | 539 |
| Losartan Potassium | Losartan Potassium | 1063 | 298 |
| Amlodipine Besylate | Amlodipine Besylate | 958 | 302 |
| Levothyroxine Sodium | Levothyroxine Sodium | 815 | 214 |
| Metformin Hcl | Metformin Hcl | 729 | 227 |
| Gabapentin | Gabapentin | 652 | 201 |
| Pantoprazole Sodium | Pantoprazole Sodium | 650 | 184 |
| Famotidine | Famotidine | 577 | 197 |
| Eliquis | Apixaban | 516 | 92 |
| Tamsulosin Hcl | Tamsulosin Hcl | 479 | 145 |
| Metoprolol Succinate | Metoprolol Succinate | 451 | 134 |
| Furosemide | Furosemide | 441 | 119 |
| Lisinopril | Lisinopril | 437 | 124 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 435 | 146 |
| Ozempic | Semaglutide | 410 | 104 |
| Carvedilol | Carvedilol | 398 | 117 |
| Ezetimibe | Ezetimibe | 332 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 318 | 93 |
| Montelukast Sodium | Montelukast Sodium | 309 | 100 |
| Hydralazine Hcl | Hydralazine Hcl | 298 | 94 |
| Omeprazole | Omeprazole | 289 | 99 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 283 | 108 |
| Pioglitazone Hcl | Pioglitazone Hcl | 282 | 88 |
| Diclofenac Sodium | Diclofenac Sodium | 279 | 126 |
| Allopurinol | Allopurinol | 274 | 73 |
| Tramadol Hcl | Tramadol Hcl | 267 | 98 |
| Farxiga | Dapagliflozin Propanediol | 253 | 80 |
| Azithromycin | Azithromycin | 241 | 194 |
| Irbesartan | Irbesartan | 236 | 75 |
| Clopidogrel | Clopidogrel Bisulfate | 216 | 67 |
| Jardiance | Empagliflozin | 207 | 67 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 207 | 35 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 205 | 50 |
| Finasteride | Finasteride | 203 | 68 |
| Glimepiride | Glimepiride | 192 | 52 |
| Fluticasone Propionate | Fluticasone Propionate | 181 | 77 |
| Metoprolol Tartrate | Metoprolol Tartrate | 176 | 45 |
| Potassium Chloride | Potassium Chloride | 170 | 56 |
| Trazodone Hcl | Trazodone Hcl | 168 | 45 |
| Baclofen | Baclofen | 151 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 151 | 60 |
| Azelastine Hcl | Azelastine Hcl | 150 | 75 |
| Alendronate Sodium | Alendronate Sodium | 149 | 48 |
| Celecoxib | Celecoxib | 149 | 68 |
| Breo Ellipta | Fluticasone/Vilanterol | 144 | 36 |
| Lorazepam | Lorazepam | 144 | 35 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 144 | 78 |
| Spironolactone | Spironolactone | 142 | 44 |
| Prednisone | Prednisone | 140 | 78 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 32 |
| Torsemide | Torsemide | 126 | 48 |
| Alprazolam | Alprazolam | 124 | 39 |
| Sertraline Hcl | Sertraline Hcl | 117 | 51 |
| Tradjenta | Linagliptin | 108 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 106 | 28 |
| Zolpidem Tartrate | Zolpidem Tartrate | 100 | 34 |
| Repaglinide | Repaglinide | 98 | 27 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 84 |
| Mirtazapine | Mirtazapine | 96 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 96 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 95 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 92 | 20 |
| Levetiracetam | Levetiracetam | 92 | 15 |
| Linzess | Linaclotide | 91 | 22 |
| Memantine Hcl | Memantine Hcl | 91 | 31 |
| Atenolol | Atenolol | 90 | 22 |
| Lidocaine | Lidocaine | 89 | 33 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 88 | 68 |
| Tresiba Flextouch U-100 | Insulin Degludec | 88 | suppressed |
| Calcitriol | Calcitriol | 86 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 86 | 32 |
| Fluconazole | Fluconazole | 83 | 42 |
| Prolia | Denosumab | 82 | 53 |
| Ondansetron Odt | Ondansetron | 80 | 55 |
| Januvia | Sitagliptin Phosphate | 79 | 19 |
| Novolog Flexpen | Insulin Aspart | 76 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 75 | 52 |
| Metformin Hcl Er | Metformin Hcl | 75 | 23 |
| Hydrocortisone | Hydrocortisone | 73 | 30 |
| Cephalexin | Cephalexin | 71 | 59 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 69 | 18 |
| Myrbetriq | Mirabegron | 69 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 68 | 14 |
| Glipizide | Glipizide | 67 | 29 |
| Bupropion Xl | Bupropion Hcl | 66 | 17 |
| Nystatin | Nystatin | 66 | 38 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 65 | 11 |
| Divalproex Sodium | Divalproex Sodium | 65 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 22 |
| Amiodarone Hcl | Amiodarone Hcl | 64 | 17 |
| Simvastatin | Simvastatin | 64 | 23 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 62 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | 23 |
| Clonazepam | Clonazepam | 59 | 12 |
| Nystop | Nystatin | 59 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 58 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 56 | 19 |
| Dapagliflozin | Dapagliflozin Propanediol | 55 | 24 |
| Lactulose | Lactulose | 55 | 15 |
| Pregabalin | Pregabalin | 55 | 18 |
| Meclizine Hcl | Meclizine Hcl | 52 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 35 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 12 |
| Icosapent Ethyl | Icosapent Ethyl | 51 | 19 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 50 | 24 |
| Cefuroxime | Cefuroxime Axetil | 49 | 46 |
| Midodrine Hcl | Midodrine Hcl | 49 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 49 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | 14 |
| Xarelto | Rivaroxaban | 47 | 21 |
| Aripiprazole | Aripiprazole | 46 | 11 |
| Rybelsus | Semaglutide | 46 | 18 |
| Temazepam | Temazepam | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 45 | 11 |
| Estradiol | Estradiol | 43 | 18 |
| Mounjaro | Tirzepatide | 43 | 15 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 43 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 42 | 12 |
| Enulose | Lactulose | 42 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 41 |
| Buspirone Hcl | Buspirone Hcl | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 41 | suppressed |
| Valsartan | Valsartan | 41 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Xtampza Er | Oxycodone Myristate | 39 | suppressed |
| Folic Acid | Folic Acid | 38 | 13 |
| Labetalol Hcl | Labetalol Hcl | 38 | 11 |
| Latanoprost | Latanoprost | 38 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 17 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | 14 |
| Movantik | Naloxegol Oxalate | 37 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 36 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 36 | 31 |
| Synthroid | Levothyroxine Sodium | 36 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | 12 |
| Olanzapine | Olanzapine | 35 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 35 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 34 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | suppressed |
| Methotrexate | Methotrexate Sodium | 33 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 33 | 13 |
| Lovastatin | Lovastatin | 32 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 29 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 26 |
| Ibuprofen | Ibuprofen | 28 | 17 |
| Megestrol Acetate | Megestrol Acetate | 28 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 28 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Scopolamine | Scopolamine | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 11 |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Methimazole | Methimazole | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 19 |
| Digoxin | Digoxin | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 24 |
| Arnuity Ellipta | Fluticasone Furoate | 25 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 25 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 25 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 25 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 24 | suppressed |
| Amantadine | Amantadine Hcl | 23 | suppressed |
| Colchicine | Colchicine | 23 | 12 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Meloxicam | Meloxicam | 21 | suppressed |
| Metolazone | Metolazone | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | 12 |
| Multaq | Dronedarone Hcl | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Mupirocin | Mupirocin | 18 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 18 | suppressed |
| Sulfasalazine | Sulfasalazine | 18 | suppressed |
| Timolol Maleate | Timolol Maleate | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Oxycontin | Oxycodone Hcl | 17 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 17 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 17 | suppressed |
| Alvesco | Ciclesonide | 16 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 16 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Letrozole | Letrozole | 15 | suppressed |
| Methylprednisolone | Methylprednisolone | 15 | 13 |
| Procrit | Epoetin Alfa | 15 | suppressed |
| Procto-Med Hc | Hydrocortisone | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Acetazolamide | Acetazolamide | 14 | suppressed |
| Anastrozole | Anastrozole | 14 | suppressed |
| Benzonatate | Benzonatate | 14 | 12 |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Proctozone-Hc | Hydrocortisone | 12 | suppressed |
| Tobramycin Sulfate | Tobramycin Sulfate | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Constulose | Lactulose | 11 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,043.22 · 84 records | Bayer Healthcare Pharmaceuticals Inc. | ABRYSVO, AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FANAPT, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FREESTYLE LIBRE 3, GARDASIL 9, GEMTESA, HETLIOZ, JARDIANCE, JASCAYD, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OFEV, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SUBLOCADE, UBRELVY, Veozah, Wegovy, ZAVZPRET, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error